(Issue 3; posted March 5, 1997; archived April 18, 1997)
Finding where and when genes are expressed is essential to deciphering their functions, especially when the genes are discovered in an anonymous way such as in a genome project. Several companies are using chips with microprinted cDNA clones or synthesized oligonucleotides to analyze the expression of thousands of genes at once.
Ignore all claims from genome-project proponents that gene discovery
is dead. Until the function of each and every gene is determined, it will be vital to
rediscover genes in different contexts so they can be placed in the right part of
the biological puzzle. Synteni, in Palo Alto, California, is promoting one of the
more recently devised methods of gene discovery and rediscovery, which uses
arrays of complementary DNA (cDNA) clones on chips. The chips can assess the
relative expression levels of thousands of genes simultaneously, information that
can be used in drug-discovery projects, diagnosis, toxicology and basic research.
Genes whose expression increases or decreases under a particular condition can
be pulled out and studied as potential regulators or effectors of that condition.
The technology In 1992 Patrick Brown of Stanford University was contemplating
a forbidding task - a complex hybridization involving many probes and many
targets that would help him in a linkage-mapping experiment. It occurred to
Brown that hybridization technology could be pushed a great deal further with
some intelligent engineering, and to take on this project he enlisted Dari Shalon,
Mark Schena and Ron Davis. Shalon, now president and CEO of Synteni, was
a doctoral student in Brown's laboratory at the time. The results of their labors were published in Science in 1995. "The principles are very simple,"
says Brown, "and it's very robust." A robotic device dips tiny capillaries into the
wells of a standard microwell plate containing solutions of individual cDNAs. Loading
of the solution into the capillaries is driven by surface tension, and the solutions
are "printed" onto a glass slide with a gentle tap. The robot offsets the next set
of samples slightly so clones can be deposited with as little as 100 ?m between
them. The DNA is linked to the slide by various chemistries, heat-denatured,
and probed with mixtures of other cDNAs that have fluorescent markers attached.
If the fluorescent probes stick, the hybridization is detected by a laser confocal
scanner.
Why is this useful? The choice of glass chips and fluorescent detection is
not random. Fluorescent signals do not disperse and so can be used at
high density. More importantly, several fluorescent detectors can be used at
once. This allows the expression levels of large numbers of genes to be
compared simultaneously. In the original Science paper, for example, the
authors probed a panel of plant cDNAs with total cDNA obtained from root and
leaf mRNA. A clone that hybridized with the leaf probe more strongly than with
the root probe would obviously be of interest to a researcher studying leaf
development or physiology. Since then, the Stanford and Synteni groups have
analyzed samples collected both before and after heat shock, addition of
phorbol esters (activators of growth-promoting signal-transduction pathways)
and addition of a chromosome 6 fragment that suppresses the tumorigenic
properties of a human melanoma cell line. Synteni now has a long list of clients, including a number
of the largest pharmaceutical companies. The company does not disclose the
nature of these projects, but Shalon says they fall into several classes. The
most exciting type of project involves the direct identification of a drug target.
The target gene is identified on the basis of its increased expression in a cell
where a target pathway (such as an inflammatory response) is known to be
activated. In theory, Synteni should be able to evaluate entire pathways, identifying, for
example, all genes whose expression is regulated by a particular transcription
factor. A second type of project uses smaller chips displaying a few well-characterized
clones to provide an initial toxicity screen for drug candidates. Using this screen,
Synteni can detect whether cells treated with a compound increase the expression
of damage-induced genes; if so, animal testing is less likely to be warranted.
Finally, the chips can be used for the diagnosis of certain disease states that have
characteristic patterns of gene expression. The competition - cDNA analysis In an area with so many applications it is not surprising that
Synteni is not alone. Hyseq, of Sunnyvale, California, uses two techniques
originally developed for DNA sequencing to provide much the same types of
information that Synteni does. Radoje Drmanac, senior vice president for research,
explains that in the first technique, Hyseq arrays random clones from cDNA
libraries on membranes, then hybridizes a series of oligonucleotides to the
clones (usually 300 distinct hybridizations, each with a different 7-mer). Clones
that show identical hybridization patterns are deduced to be identical, and their
frequency in an array gives a measure of their expression level. "It's a more
cumbersome approach," says Shalon, pointing out that each sample must be
hybridized many times and that the number of cDNA clones that must be
arrayed is very large. Drmanac counters with the assertions that Hyseq has
the ability to array enough clones, and that any approach using cDNAs should
attempt such coverage in any case. "This holistic approach is critical," he says.
Synteni uses similar arrays of random cDNAs in some cases, primarily for gene
discovery. Testing known genes Some of the applications mentioned above do not require
gene discovery, using instead arrays of known genes. As genome projects
advance, arrays of known genes or expressed sequence tags (ESTs) will
expand, and probably replace the redundant random cDNA arrays even in target
discovery projects. The Synteni technique can be directly adapted to this approach,
and ~50% of their chips already contain known cDNAs. Hyseq have developed a
second technique to monitor known genes, in which they spot arrays of
oligonucleotides, hybridize cDNAs, and then probe with a second set of oligonucleotides.
The double-hit hybridization process means that they only need two probe sites
per gene. Their largest array can monitor the expression of 100,000 genes in
384 cm2. The competition - oligonucleotides The closest competition in oligonucleotide-chip technology is,
however, Affymetrix, Inc., of Palo Alto, California. Affymetrix, founded in
1992 as a daughter company of Affymax N.V., forms its arrays of
oligonucleotides by direct synthesis on the chip instead of "printing" spots of
pre-made cDNAs. Affymetrix has been using its chips for DNA sequencing, but have
recently entered the area of expression-level analysis. Affymetrix's technology uses a photolithographic mask to allow
photolabile groups to be deprotected selectively according to their precise position on
the chip, and builds up oligonucleotides by repeated cycles of deprotection and coupling.
Up to 400,000 different oligonucleotides are routinely synthesized on a ~1.6-cm2 chip.
A gene can be represented by 20 different oligonucleotides plus 20 mismatch oligonucleotides
as controls, so the expression levels of up to 10,000 genes can be measured on a
single chip. This gene density doesn't yet reach that of a Synteni chip, although these
densities are constantly evolving. The two companies have a well-developed debate
about which approach works best (Table 1). On one of the
most important issues, specificity, both sides claim superiority for different reasons. Does more complicated technology always win? Shalon doesn't think so. "So far we
haven't lost a single customer to Affymetrix," he says. For now it seems that, despite
all the claims of great speed by both companies, there is more than enough work to go
around. Endlinks To read all about, and see, MicroArrays, go to The Brown Lab MicroArray
home page. Written for members of the scientific community, it provides pages of
information about the production, use and applications of MicroArrays. In
addition to reading the text and looking at the photos, you can download movies
of the equipment in action.
(See Figure 1, a sample experiment using a Synteni chip.)
William Wells, Ph.D., is a scientific journalist with Biotext, Ltd. in San Francisco, California.
For a link to nine other links that will lead you to the history, goals and budget of the human genome projects go to Human Genome Project
For a review or quick check on standard procedures every gene hunter knows about, try Genentech's Access Excellence Web site. It covers procedures related to biotechnology and recombinant DNA protocols.
For information on Synteni, Inc., the company, its services and its products, see Synteni's Web site.
Affymetrix, Inc.'s home page is a well designed, easy to use site providing information about the company's products, research and investor and business news. For information about Affymetrix products including gene chip technology, the site to visit is :Affymetrix products.
Glaxo Wellcome's view of its junior company Affymax is online at Affymax. For Glaxo Wellcome's view of itself, see Glaxo Wellcome.
For lucid overview of the creation of cDNA libraries, visit : cDNA.
As the web page says, "HYBsimulator oligonucleotide software can do hybridization simulation! HYBsimulator Version 2.0 is the most oligonucleotide software you will ever need!" See for yourself at :HYBsimulator software.
Oligonucleotide Probe Database: OPD is a hyperlinked database of oligonucleotide sequences and associated experimental information which may be useful to scientists interested in using oligonucleotide probes in their research. See oligonucleotides.
Roswell Park Cancer Institute Related links - Genetics resources on the Web.
